Plus de 50 ans d’expérience à votre service

Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr

Stock épuisé.
En rupture de stock
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte

 

 

100 µg

Ref. AG-25B-0038-C100
AdipoGen Life Sciences

photos non contractuelles

Neuf 210.00 H.T.

Quantité

Alerte réapprovisionnement
Recevez une alerte par email dès que votre choix sera de retour en stock
Votre e-mail*:

Détails Produit

Product description: Polyclonal Antibody. Recognizes full-length mouse NLRC5. Does not cross-react with human NLRC5. Application: WB. Source: Rabbit. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. Major histocompatibility complex class I molecules are expressed in all nucleated cells, whereas MHC class II molecules are mostly expressed in hematopoietic cells. The tight regulation of both MHC class I and class II molecules is crucial for eliciting an appropriate immune response. The MHC class II and class I molecule regulation is controlled by class II MHC transactivator (CIITA) and by NLR family caspase recruitment domain?containing 5 (NLRC5), respectively. NOD-like receptor family CARD domain containing 5 (NLRC5) is the largest member of the NOD-like receptors (NLRs) family. As all NLR-family members, NLRC5 shares a similar protein structure consisting of three main domains: a variable N-terminal protein-interaction domain, a central Nucleotide-Binding Domain (NBD) and a C-terminal stretch consisting of Leucine Rich Repeats (LRRs). NLRC5 contains between its CARD and NBD domain a bipartite-type nuclear localization signal (NLS), allowing NLRC5 transport towards the nucleus. The expression levels of NLRC5 and MHC class I are highly correlated, with more NLRC5 resulting in more MHC class I expression and increased MHC class I cell surface levels. NLRC5 is highly expressed in hematopoietic cells and tissues such as the spleen, lymph node, thymus, intestine, lung and bone marrow. NLRC5 is inducible by interferon?gamma (IFN?gamma). NLRC5 is decreased in tumor tissues of most cancer types. Lower NLRC5 expression is associated with reduced survival in melanoma, rectal, bladder, uterine, cervical and head/neck cancer.

Lien vers la Fiche Technique